ReviewAnti-inflammatory & anti-allergy agents in medicinal chemistry2026
Microsponge Drug Delivery Systems: Advancing the Therapeutic Efficacy of Anti-Inflammatory Medications.
Review in Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microsponge drug delivery systems represent an innovative approach to enhancing the therapeutic efficacy of anti-inflammatory drugs through controlled release, improved bioavailability, and targeted delivery. These porous polymeric microspheres, ranging from 5 to 300 μm, encapsulate active pharmaceutical ingredients (APIs) to achieve sustained drug release, minimizing systemic side effects and dosing frequency. Chronic inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease (IBD), and psoriasis, often require prolonged treatment, but conventional therapies such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are limited by systemic toxicity and frequent administration. Microsponges address these challenges by enhancing drug stability, increasing retention at the target site, and reducing systemic exposure. Advanced fabrication techniques, including emulsion solvent diffusion, liquid-liquid suspension polymerization, and electrohydrodynamic atomization, allow precise control over microsponge properties, optimizing drug loading and release kinetics. In arthritis, microsponges extend anti-inflammatory activity; in IBD, they enable colon-specific delivery; and in psoriasis, they enhance drug penetration through keratinized plaques. These systems improve patient compliance by reducing dosing frequency and minimizing adverse effects. Despite their promise, further research is needed to optimize formulations, evaluate long-term safety, and fully explore their potential in managing chronic inflammatory diseases. Microsponge technology offers a transformative platform for improving therapeutic outcomes, paving the way for innovative treatments in pharmaceutical and clinical applications.
Indexed as
Identifiers
41355543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.